Bakhos A. Tannous, PhD

Executive Director, Head of Rare Cancer @AstraZeneca @Alexion Former Professor @Harvardmed Firm to find CURE for #RareCancer #GBM #DIPG #Sarcoma

[Bakhos A. Tannous, PhD @TannousLab]

May is Brain Tumor Awareness Month.
@AstraZeneca and @AlexionPharmaUS , we are committed to advancing rare oncology research—including brain tumors—where innovation can make the greatest impact on patients and families.
#BrainTumorAwareness #RareDisease #Oncology #Innovation

[Cancer Cell @Cancer_Cell]

Online Now: Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity https://t.co/SukHzomNr9

[Brain Tumor Network @BTNcares]

We're fueling your Friday with positivity and motivation

[Cancer Cell @Cancer_Cell]

Online Now: A photoreceptor state links aggressive brain tumors in children https://t.co/KvRcGIi1UZ

[nature @Nature]

CAR T cells are laboratory-engineered immune cells that provide effective treatment for some cancers. Progress is being made towards creating these cells in vivo

https://t.co/Zht4rpioSK

[Bakhos A. Tannous, PhD @TannousLab]

#Thanksgiving is not only to be greatful for all the "good" in our life, but also reflect on the “bad" and recommit our energies to giving thanks and just "#giving". Happy and blessed thanksgiving to everyone who celebrates it

[Cancer Cell @Cancer_Cell]

Brain metastasis: From etiology to ecotypes https://t.co/9DztVwNmLi

[Toni Choueiri, MD @DrChoueiri]

The role of ultra-processed food (UPF) in obesity | ⁦@NatureRevEndo⁩ —time to sound the alarm 🚨 on UPF! Nice review that focus on the biological link between UPF and Obesity https://t.co/J2QIrmGn9Y

[Cancer Cell @Cancer_Cell]

Pan-cancer human brain metastases atlas at single-cell resolution https://t.co/s3IClv0DQH

[Cell @CellCellPress]

In the latest issue! Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis https://t.co/1xyMQK4fQU

[Editor - Neuro-Oncology Advances @EditorNeuro]

Recent research found that #temozolomide rechallenge is a common, safe, and effective second-line option for patients with MGMT-methylated, #IDHwildtype #GBM following first-line lomustine/temozolomide therapy.

Read the full article in our latest issue: https://t.co/5G6e5O29eV

[NEJM AI @NEJM_AI]

Policy Corner by Abdullah H. Ishaque, MD, PhD (@ahishaque), @AbdiAidid, JD, LLM, and @gelarehzadeh, MD, PhD: Lessons from the Failure of Canada’s Artificial Intelligence and Data Act https://t.co/UyJakYUWZI

#AIinMedicine

[Gomes Lab @lab_gomes]

Super excited to share our newest piece out today @NatureRevCancer linking age-induced metabolic reprogramming to cancer development. https://t.co/MbiKYAAAkg

[Bakhos A. Tannous, PhD @TannousLab]

🟡 July is #sarcomaawarenessmonth 🟡
Sarcoma is a rare and often overlooked cancer, but its impact is deeply felt by every patient and family it touches. @AstraZeneca and @AlexionPharmaUS, we are committed to transforming outcomes for patients with rare cancers like #sarcoma

[Eric Topol @EricTopol]

The more potent and bespoke immunotherapy vs cancer, the better. Today's example is a neoantigen vaccine vs melanoma
https://t.co/S1fwep101y

[Cancer Cell @Cancer_Cell]

Online Now: KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer https://t.co/R2syuA5ALW

[Bakhos A. Tannous, PhD @TannousLab]

Excited to lead efforts across discovery and clinical strategy to bring therapies for patients with rare cancers where the need is great and the impact can be life-changing. It’s an honor to join a team so dedicated to advancing science and making a real difference for patients

[Bakhos A. Tannous, PhD @TannousLab]

I'm happy to share that I’ve started a new position as Executive Director, Head of Rare Cancer Discovery @AstraZeneca and @AlexionPharmaUS

Looking forward to what’s ahead!

[Immunity @ImmunityCP]

Online now: Niche-specific therapeutic targeting of myeloid cells in the central nervous system https://t.co/V5DGFontx1

[giuseppe Minniti @gminniti2012]

Good update of recommendation for LGG management in the era of vorssidenib. More trials in progress
@EANOassociation
@EORTC
@SapienzaRoma
@ESTRO_RT
@myESMO